Profile data is unavailable for this security.
About the company
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
- Revenue in INR (TTM)43.33bn
- Net income in INR8.54bn
- Incorporated1979
- Employees7.84k
- LocationAjanta Pharma LtdAjanta House,, Charkop, Kandivli West,MUMBAI 400067IndiaIND
- Phone+91 2 266061000
- Fax+91 2 266061200
- Websitehttps://www.ajantapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 230.31bn | 14.86k | 36.57 | -- | 25.44 | 3.65 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Laurus Labs Ltd | 50.54bn | 1.48bn | 255.64bn | 6.01k | 172.87 | -- | 46.25 | 5.06 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Natco Pharma Ltd. | 42.21bn | 16.37bn | 257.25bn | 4.02k | 15.72 | -- | 14.10 | 6.09 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Pfizer Ltd | 22.25bn | 6.09bn | 263.45bn | 1.72k | 43.30 | -- | 39.33 | 11.84 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 277.60bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Gland Pharma Ltd | 58.58bn | 7.22bn | 279.84bn | 4.22k | 38.75 | -- | 25.60 | 4.78 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 280.54bn | 5.31k | 48.84 | -- | 38.18 | 7.81 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Piramal Pharma Ltd | 83.73bn | 277.60m | 292.00bn | 6.72k | 1,050.21 | -- | 37.47 | 3.49 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 305.15bn | 1.05k | 126.76 | -- | 103.12 | 32.65 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Ajanta Pharma Ltd | 43.33bn | 8.54bn | 417.87bn | 7.84k | 49.35 | -- | 42.21 | 9.64 | 67.79 | 67.79 | 343.97 | -- | -- | -- | -- | 5,523,445.00 | -- | 16.61 | -- | 20.47 | 75.01 | 73.22 | 19.71 | 19.31 | -- | -- | -- | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
IPCA Laboratories Ltd | 82.12bn | 5.77bn | 419.89bn | 17.34k | 72.79 | -- | 44.25 | 5.11 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
GlaxoSmithKline Pharmaceuticals Limited | 35.07bn | 6.40bn | 471.53bn | 3.21k | 73.69 | -- | 66.43 | 13.45 | 37.77 | 37.77 | 206.98 | -- | -- | -- | -- | 10,920,890.00 | -- | 11.01 | -- | 17.88 | 61.97 | 55.77 | 18.25 | 12.25 | -- | 490.08 | -- | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Glenmark Pharmaceuticals Ltd | 120.21bn | -15.73bn | 505.30bn | 14.99k | -- | -- | -- | 4.20 | -55.78 | -46.50 | 425.96 | -- | -- | -- | -- | 8,020,026.00 | -- | 1.02 | -- | 1.43 | 63.93 | 59.47 | -12.71 | 1.43 | -- | 1.78 | -- | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Abbott India Ltd | 59.28bn | 12.39bn | 612.16bn | 3.81k | 49.41 | -- | 46.68 | 10.33 | 583.08 | 583.08 | 2,789.54 | -- | -- | -- | -- | 15,541,480.00 | -- | 20.92 | -- | 28.59 | 45.28 | 44.20 | 20.90 | 17.26 | -- | 119.46 | -- | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
Holder | Shares | % Held |
---|---|---|
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jul 2024 | 4.28m | 3.40% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Jul 2024 | 3.70m | 2.94% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 1.63m | 1.29% |
Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2024 | 1.55m | 1.23% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jul 2024 | 1.43m | 1.14% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jul 2024 | 1.37m | 1.09% |
Canara Robeco Asset Management Co. Ltd.as of 31 Jul 2024 | 1.33m | 1.05% |
White Oak Capital Partners Pte Ltd.as of 30 Jun 2023 | 1.18m | 0.94% |
Tata AIA Life Insurance Co. Ltd.as of 31 Jul 2024 | 1.16m | 0.92% |
Invesco Asset Management (India) Pvt Ltd.as of 31 Jul 2024 | 979.42k | 0.78% |